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Abstract 
Review on CASP8, with data on DNA/RNA, on the 
protein encoded and where the gene is implicated. 
Identity 
Other names: ALPS2B, CAP4, Casp-8, FLICE, 
MACH, MCH5 
HGNC (Hugo): CASP8 
Location: 2q33.1 
Local order: CASP8 is located on chromosome 2 
on the long arm (positive strand), and lies between 
the CASP10 and STRADB genes. 
DNA/RNA 
Description 
54269 bases with 11 exons. 
Transcription 
There are 6 transcriptional variants of CASP8 and  
 
 
they are described in Table 1. 
Protein 
Note 
Caspases are a family of cysteinyl aspartate specific 
proteases which are synthesized as zymogens. 
Caspase-8 was discovered as a component of the 
CD95 (Fas/APO-1) death-inducing signaling 
complex (DISC) (Muzio et al., 1996). 
Description 
Caspase-8 has a number of isoforms, including 
procaspase-8a (496 aa), procaspase-8b (479 aa), 
procaspase-8c (464 aa), procaspase-8e (235 aa), 
procaspase-8g or caspase-8L (538 aa) and caspase-
8 short (108 aa). 
Only two isoforms are predominantly expressed in 
many different tissues and cell lines: procaspase-8a 
and procaspase-8b (Scaffidi et al., 1997). 
They act as the main initiator caspases in death 
receptor-induced apoptosis. 
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Caspase-8L was reported to be expressed in human 
peripheral blood lymphocytes as a truncated 
protein, which lacks the C-terminal protease 
domain (Horiuchi et al., 2000).  
Therefore, it is suggested that caspase-8L is 
recruited into the DISC but remains proteolytically 
inert, interfering with the transduction of the signal 
from the DISC (Himeji et al., 2002). 
An isoform that is detected in bone marrow 
mononuclear cells is named caspase-8 short. 
Although it only contains the first DED and a part 
of the second DED, overexpression of caspase-8 
short is reported to increase sensitivity to apoptosis 
(Xu et al., 2009). 
In addition to caspase-8 isoforms, there is a number 
of cleavage products described, which are formed 
in the course of apoptosis.  
Apoptotic processing of procaspase-8a/b involves 
generation of the cleavage products p43/p41, p30, 
the prodomains p26/p24, p18 and p10 (Hoffmann et 
al., 2009).  
The latter two cleavage products form the active 
caspase-8 heterotetramer p102-p182 that triggers 
apoptosis (Lavrik and Krammer, 2012). 
Expression 
Caspase-8 is expressed in almost all kind of tissues, 
with the highest expression in the immune system 
and lowest in the nervous system (McCall et al., 
2011). 
Localisation 
Procaspase-8 mainly localizes to the cytosol, in 
close proximity to the membrane (Medema et al., 
1997).  
It may also localize to mitochondria (Qin et al., 
2001; Chandra et al., 2004) or centrosomes (Mielgo 
et al., 2009).  
Caspase-8 cleavage products are reported to 
localize to the nucleus as well as the cytosol 
(Benchoua et al., 2002; Yao et al., 2007). 
Function 
Caspase-8 is the main initiator caspase in death 
receptor-induced apoptosis.  
Upon stimulation, procaspase-8 is recruited to the 
CD95 or TRAIL DISC, or TNF complex II. 
Procaspase-8 activation involves dimerization, 
oligomerization and cleavage (Schleich et al., 
2012).  
The cleavage of procaspase-8 involves several 
steps, leading to the generation of the active 
caspase-8 heterotetramer p102-p182 (Lavrik and 
Krammer, 2012).  
Depending on the cell type, active caspase-8 either 
directly cleaves effector caspases (caspase-3 and 
caspase-7) or cleaves Bid, which eventually leads to 
release of cytochrome C and apoptosome formation 
followed by cleavage of effector caspase-3, 
caspase-6 and caspase-7 by procaspase-9 (Scaffidi 
et al., 1998; Scaffidi et al., 1999). 
In addition to apoptosis, caspase-8 has a role in 
programmed necrosis (necroptosis) as well. 
Caspase-8 can be recruited to the necroptotic 
complexes (necrosome or ripoptosome) together 
with RIP1, RIP3 and FADD.  
 
Chromosomal location of CASP8 and nearby genes. 
 
It would then cleave RIP1 and RIP3, and therefore 
block necroptosis (Stupack et al., 2006; Feoktistova 
et al., 2011; Tenev et al., 2011). 
Caspase-8 also has an essential role for NF-kB 
signaling via many different stimuli including 
CD95, TRAIL, TCR and TLR stimulations 
(Kataoka and Tschopp, 2004; Dohrman et al., 2005; 
Su et al., 2005; Lemmers et al., 2007; Grunert et al., 
2012).  
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Schematic representation of the structure of the 54kb CASP8 gene, which contains 10 exons and can be transcribed into 6 
alternative splice variants. 
 
 
Interestingly, although the activation of procaspase-
8 to p102-p182 heterotetramer is necessary for 
MAPK signaling (Kober et al., 2011), it is not 
necessary for NF-kB signaling upon CD95 
stimulation (Neumann et al., 2010). 
Caspase-8 has been also reported to affect 
metastasis. Interestingly, although loss of caspase-8 
potentiates metastasis, under conditions where 
apoptosis is compromised, caspase-8 can promote 
tumor cell migration and metastasis (Stupack et al., 
2006; Barbero et al., 2009). 
Homology 
Caspase-10, FADD, c-FLIP. 
Mutations 
Germinal 
A homozygous C to T mutation at residue 248 leads 
to familial autoimmune lymphoproliferative 
syndrome type 2B. 
Somatic 
Various somatic mutations of CASP8 are identified 
in different carcinomas. Mutations are observed at 
different parts of caspase-8, but they all lead to a 
catalytically inactive form. 
- Hepatocellular carcinoma: CASP8 is frequently 
inactivated by the frameshift somatic mutation 
1225-1226delTG in hepatocellular carcinomas, 
resulting in a premature termination of amino-acid 
synthesis in the p10 protease subunit (Soung et al., 
2005b). 
- Gastric carcinoma: Inactivating CASP8 mutations 
are detected at different sites in about 10% of 
advanced gastric carcinomas (Soung et al., 2005a). 
- Colorectal carcinoma: Inactivating CASP8 
mutations are detected at different sites in about 5% 
of invasive colorectal carcinomas (Kim et al., 
2003). 
- Vulvar squamous carcinoma: Deletion of leucine 
62 (∆Leu62casp-8) is detected in A431 human 
vulvar squamous carcinoma cells. ∆Leu62casp-8  
has a shorter half-life than wild-type caspase-8 and 
cannot interact with caspase-8 or FADD; therefore 
lost its proapoptotic activity (Liu et al., 2002). 
- Head and neck carcinoma: A mutation was 
detected in the tumor cells from head and neck 
carcinoma that modifies the stop codon and 
lengthening the protein by 88 amino acids 
(Mandruzzato et al., 1997). 
- Neuroblastoma : An Alanine to Valine missense 
mutation was detected at codon 96 in a 
neuroblastoma sample which lacks CASP8 mRNA 
expression (Takita et al., 2001). 
Implicated in 
Hepatocellular carcinoma 
Disease 
Hepatocellular carcinoma accounts for the majority 
of liver cancers. Mostly, it is secondary to cirrhosis, 
which is caused mainly by alcohol abuse or 
hepatitis B/C infections. A somatic mutation in 
CASP8 leading to deletion of the bases 1225-1226 
was detected in 9 out of 69 hepatocellular 
carcinoma samples from unrelated patients. This 
deletion results in a frameshift and therefore 
premature termination of amino-acid synthesis in 
the p10 protease subunit, consequently inactivating 
caspase-8 (Soung et al., 2005b). 
Gastric carcinoma 
Disease 
Gastric carcinomas arise from the epithelium of the 
stomach. In a study by Soung and colleagues 
(Soung et al., 2005a), 122 advanced gastric 
carcinoma samples were analyzed for mutations in 
the coding region and the exon-intron junctions of 
CASP8 gene by PCR-SSCP analysis. In 13 
samples, mutations in caspase-8 were found. All 
mutants were still expressed at a similar level 
compared to wild-type caspase-8, however, when 
transfected into cell lines, all mutants except one 
showed defects in apoptosis. 
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Involvement of procaspase-8 in death-receptor signaling. (A) Procaspase-8 is recruited to the CD95 or TRAIL DISC through 
the adaptor protein FADD. Upon activation of TNF, procaspase-8 is recruited through FADD and TRADD. For activation, 
procaspase-8 requires dimerization and internal cleavage. The major function of procaspase-8 in DR signaling is induction of 
apoptosis, but it also regulates necroptosis or NF-kB via RIP1/RIP3 and c-FLIP(L). (B) Procaspase-8 consists of a prodomain 
harboring tandem death effector domains (DED) followed by one large (p18) and one small (p10) catalytic subunit. Cleavage 
between p18 and p10 generates the intermediate p43/p41 which is further processed to the fully active form by cleavage 
between the prodomain and p18. 
 
 
Colorectal carcinoma 
Disease 
Colorectal cancer arises from colon, rectum or 
appendix. In the analysis of 82 colorectal adenomas 
and 98 invasive colorectal carcinomas, 5 mutations 
were detected only in the colorectal carcinomas but 
not in the adenomas. 3 out of 5 of these mutations 
acted in a dominant negative manner and 
suppressed apoptosis (Kim et al., 2003). 
Vulvar squamous carcinoma 
Disease 
In the analysis of A431 human vulvar squamous 
carcinoma cells, a mutation in CASP8 leading to 
deletion of leucine 62 was detected. This mutant 
version of caspase-8 retained its enzymatic activity, 
however, it lost the ability to interact with itself, 
wild-type caspase-8 or FADD and therefore lost its 
proapoptotic activity (Liu et al., 2002). 
Head and neck carcinoma 
Disease 
Head and neck carcinomas start in the lip, oral 
cavity, nasal cavity, paranasal sinuses, pharynx, or 
larynx and the majority (90%) originates from the 
epithelium, therefore named squamous cell 
carcinomas. A mutation in CASP8 was detected in 
the cells from a tumor relapse resected from the oral 
cavity of a late-stage squamous cell carcinoma 
patient. This mutation was found to modify the stop 
codon and add an Alu repeat to the coding region. 
Therefore, the mutant protein is 88 amino acids 
longer than the wild type and cannot efficiently act 
as an apoptotic protein (Mandruzzato et al., 1997). 
Neuroblastoma 
Disease 
Neuroblastoma arises from immature nerve cells. It 
is mainly localized to adrenal medulla. In a study 
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where human neuroblastoma cells were transferred 
to chick chorioallantoic membrane, tumor 
development was monitored.  
Although presence or lack of caspase-8 did not 
change primary tumor growth, metastasis was 
highly promoted in the tumors lacking caspase-8 
due to impaired programmed cell death (Stupack et 
al., 2006).  
In a similar study, tumor cells additionally lacking 
caspase-3 were used to test non-apoptotic effects of 
caspase-8 on neuroblastoma metastasis. 
Interestingly, tumors lacking only caspase-3 
metastasized more efficiently than tumors lacking 
both caspases, pointing out that caspase-8 also 
shows non-apoptotic properties such as enhancing 
cell migration (Barbero et al., 2009). 
Silencing of caspase-8 was also observed in human 
neuroblastoma samples. In two studies by Takita 
and colleagues, 11 out of 15 and 19 out of 27 
neuroblastoma samples did not express caspase-8, 
detected by real-time PCR (Takita et al., 2000; 
Takita et al., 2001).  
Furthermore, a missense mutation was detected at 
codon 96 in one of the samples lacking caspase-8 
expression (Takita et al., 2000). 
Furthermore, silencing of CASP8 in neuroblastoma 
was found to be associated with MYCN 
amplification. 10 out of 16 patients with MYCN 
amplification had completely methylated CASP8 
alleles opposed to only 1 out of 26 patients without 
MYCN amplification.  
Interestingly, one patient among these 42 patients 
had a deletion of the CASP8 gene (Teitz et al., 
2000). 
Medulloblastoma 
Disease 
Medulloblastoma is a tumor of the brain that 
originates in the cerebellum or posterior fossa. In 
one study of medulloblastoma, 14 out of 27 tumors 
were identified to have lost CASP8 mRNA 
expression (Zuzak et al., 2002). Furthermore, 
another study showed that CASP8 expression was 
reversely correlating with the disease. The 5-year 
cumulative progression-free survival rate of the 
patients with weak CASP8 expression was 31%, 
and with moderate/strong caspase-8 expression 
73% (Pingoud-Meier et al., 2003). 
Small cell lung carcinoma 
Disease 
Small cell lung carcinomas commonly originate 
from the lung, although rarely can originate also 
from cervix, prostate or gastrointesinal tract. In this 
carcinoma, tumor cells are much smaller than 
normal cells with almost no cytoplasm. In one 
study, 13 out of 25 small cell lung carcinoma 
samples showed silencing of CASP8 due to 
methylation (Hopkins-Donaldson et al., 2003). 
Autoimmune lymphoproliferative 
syndrome type 2B 
Disease 
A homozygous C to T mutation in caspase-8 at 
residue 248 in the p18 protease subunit leads to 
autoimmune lymphoproliferative syndrome type 2B 
(Chun et al., 2002). 
Autoimmune Lymphoproliferative Syndrome Type 
2B is an autosomal dominant disease where there 
are defects in activation of T cells, B cells, and 
natural killer cells of the patients as well as in 
CD95-mediated apoptosis. Patients have 
lymphoproliferation and thus lymphadenopathy, 
splenomegaly and autoimmunity. 
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